Stay updated on MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.

Latest updates to the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 replaces the previous Revision: v3.4.1.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page now displays Revision: v3.4.1, replacing the previous v3.4.0; this is a minor version update and does not affect content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedUI updates include adding a Show glossary option, minor wording/capitalization tweaks to QC criteria and FEAR Act notices (such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and a new revision tag v3.4.0, replacing the previous v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange Detected- Footer revision label updated from Revision: v3.3.3 to Revision: v3.3.4.SummaryDifference0.0%

- Check84 days agoChange DetectedLocations were updated: new site entries by state and country (California, Florida, Kansas, Kentucky, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Washington, Ontario, Quebec) were added and corresponding per-location headings were removed, with a revision to v3.3.3.SummaryDifference1%

Stay in the know with updates to MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.